Chapter 9. C-Reactive Protein

  1. James A. de Lemos MD Associate Professor of Medicine Coronary Care Unit Director
  1. Amit Khera MD, MSc Assistant Professor of Medicine Director

Published Online: 13 JAN 2009

DOI: 10.1002/9781444300208.ch9

Biomarkers in Heart Disease

Biomarkers in Heart Disease

How to Cite

Khera, A. (2008) C-Reactive Protein, in Biomarkers in Heart Disease (ed J. A. de Lemos), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444300208.ch9

Editor Information

  1. University of Texas Southwestern Medical Center Dallas, TX, USA

Author Information

  1. Program in Preventive Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Publication History

  1. Published Online: 13 JAN 2009
  2. Published Print: 18 APR 2008

Book Series:

  1. The AHA Clinical Series

Book Series Editors:

  1. Elliott Antman

ISBN Information

Print ISBN: 9781405175715

Online ISBN: 9781444300208



  • CVD screening and C-reactive protein (CRP) testing - most promising;
  • heart disease population screening - limitations of current methods;
  • C-reactive protein and cardiovascular events;
  • Framingham Risk Score - standard US CV risk assessment;
  • C-reactive protein and atherosclerosis;
  • C-reactive protein (CRP) and adverse endothelial cell function;
  • C-reactive protein in population screening;
  • American Heart Association and Centers for Disease Control (AHA/CDC);
  • CRP embraced as leading candidate in CV risk assessment improvement


This chapter contains sections titled:

  • Introduction

  • Limitations of current methods for population screening of heart disease

  • Biology and chemical properties of C-reactive protein

  • C-reactive protein and cardiovascular events

  • C-reactive protein and atherosclerosis

  • C-reactive protein for population screening

  • Controversies regarding the clinical use of C-reactive protein

  • Conclusions

  • References